Brief: Pharnext FY Net Loss Widens To 21.3 Million Euros
24/04/2019 07:39
April 24 (Reuters) - PHARNEXT SA PHARN.PA :
* FY NET LOSS EUR 21.3 MILLION VERSUS LOSS OF EUR 20.1
MILLION
YEAR AGO
* CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 22.8 MILLION AT
DECEMBER 31ST, 2018 VERSUS EUR 12.5 MILLION AT YEAR-END 2017
* PHARNEXT HAS CONFIRMED ITS PLAN TO LAUNCH A PHASE 2B STUDY
OF
PXT864
Source text for Eikon: ID:nEQ8KXs8Za
Further company coverage: PHARN.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development